Back to discover
Disease

Common variable immunodeficiency

Late-stage therapeutic development
Also known as CVID, Common Variable Immune Deficiency, common variable agammaglobulinemia, idiopathic immunoglobulin deficiency+10 more

CVID, Common Variable Immune Deficiency, common variable agammaglobulinemia, idiopathic immunoglobulin deficiency, primary antibody deficiency, primary hypogammaglobulinemia, secondary hypogammaglobulinemia, sporadic hypogammaglobulinemia, Immunoglobulin deficiency, late-onset, acquired agammaglobulinemia, acquired hypogammaglobulinemia, common variable hypogamma-globulinemia, common variable immune deficiency, hypogamma-globulinemia, acquired.

14
Clinical trials
12
Associated genes
3
Related proteins
Current focus
B-lymphocyte cd19 biologyCd40 ligand biologyTherapeutic developmentInflammation & immunity

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 5 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones6View
Results expected 5
Recently completed 1
Activity timeline6

Clinical trials

13 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
14
All trials
6
Active
6
Late-stage
6
Completed
Late-stage studies

A Prospective Study of the Utility of Spirometry to Identify and Manage Immunoglobulin Replacement Dosage in Primary Antibody Deficiency in Patients With Potentially Reversible Airway Disease

Phase 4 · Recruiting · University of Alabama at Birmingham

A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

Phase 4 · Completed · IMMUNOe Research Centers

An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor Blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 (Leniolisib) in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Phase 2/3 · Completed · Novartis Pharmaceuticals

Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial

Phase 4 · Completed · Oslo University Hospital

A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency

Phase 3 · Completed · CSL Behring

A Multicenter Study on the Efficacy and Safety of Vivaglobin® in Previously Untreated Patients (PUPs) With Primary Immunodeficiency (PID)

Phase 4 · Completed · CSL Behring
Recently completed

An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor Blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 (Leniolisib) in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/ p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)

Phase 2/3 · Completed · Novartis Pharmaceuticals

A Single-site, Open-Label, Pilot Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

Phase 4 · Completed · IMMUNOe Research Centers

Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial

Phase 4 · Completed · Oslo University Hospital

A Multicentre Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency

Phase 3 · Completed · CSL Behring

A Multicenter Study on the Efficacy and Safety of Vivaglobin® in Previously Untreated Patients (PUPs) With Primary Immunodeficiency (PID)

Phase 4 · Completed · CSL Behring

A Pilot Study of Safety and Efficacy of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

Phase 1 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

NFKB10.72TNFRSF13B0.70ICOS0.68NFKB20.68CD190.60CR20.48IRF2BP20.47CD810.47TNFRSF13C0.44TTC7A0.44CD40LG0.40SOCS10.39

Disease biology

3 matches

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

B-lymphocyte antigen CD19via CD190.60CD40 ligandvia CD40LG0.40Uracil-DNA glycosylasevia UNG0.07

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Heterogeneous group of immunodeficiency syndromes characterized by hypogammaglobulinemia of most isotypes, variable B-cell defects, and the presence of recurrent bacterial infections.

Synonyms

CVID, Common Variable Immune Deficiency, common variable agammaglobulinemia, idiopathic immunoglobulin deficiency, primary antibody deficiency, primary hypogammaglobulinemia, secondary hypogammaglobulinemia, sporadic hypogammaglobulinemia, Immunoglobulin deficiency, late-onset, acquired agammaglobulinemia, acquired hypogammaglobulinemia, common variable hypogamma-globulinemia, common variable immune deficiency, hypogamma-globulinemia, acquired

References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.